

Supplemental Table 1: Summary of the diagnostic accuracy of serologic and fecal testing for differentiating IBD and IBS. Results with cutoff values provided. Modified by permission (40).

Test	Test cutoff	Sensitivity, range or (95% CI)*	Specificity, range or (95% CI)*	Positive likelihood ratio, range or (95% CI)*	Negative likelihood ratio, range or (95% CI)*
ESR	10-15 mm/h	0.54-0.78	0.46-0.95	1.0-16.3	0.3-0.98
CRP	5 to 6 mg/L	0.73 (0.64-0.80)	0.78 (0.58-0.91)	3.4 (1.05-5.71)	0.35 (0.27-0.42)
FL	4.0-7.25 µg/g	0.79 (0.73-0.84)	0.93 (0.63-0.99)	11.5 (-10.7-33.8)	0.22 (0.17-0.28)
Fcal	Ranges:				
	24.3 to 30 µg/g	0.92-0.98	0.96-0.98	28-59	0.01-0.07
	50 to 60 µg/g	0.81 (0.75-0.86)	0.87 (0.78-0.92)	6.12 (2.75-9.49)	0.21 (0.14-0.28)
	100-164 µg/g	0.64 (0.49-0.77)	0.90 (0.72-0.97)	6.23 (1.28-13.75)	0.4 (0.21-0.58)

Note: This is a summary of testing for any organic disease in IBS-D and chronic diarrhea and is not limited solely to IBS-D studies

Supplemental Table 2. Cardiovascular risk factors to consider when evaluating a woman with IBS-C for possible tegaserod use.

History of cardiovascular disease

History or presence of hypertension

Active smoking

History or presence of diabetes mellitus

History of presence of hyperlipidemia

Age > 55 years at baseline

Obesity (BMI > 30 kg/m² at baseline)